Companies › Airway Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Zelpultide alfa Recombinant human surfactant protein D (rhSP-D) | SFTPD | Phase 2 | Bronchopulmonary Dysplasia | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06897839 | Zelpultide alfa | Phase 2 | Bronchopulmonary Dysplasia | Other | Mar 2028 |
–
Ascendis Pharma Endocrinology Division Eirion Therapeutics Inotrem Ascendis Pharma Growth Disorders Tego Science
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.